Posts by Christine Frankovic
Christine Frankovic currently serves as Executive Director of US Field Sales at KCAS Bio, where she leads the company’s biotech-focused business development organization across the United States. In this role, she is responsible for commercial strategy, team performance, and expanding relationships with biopharma partners across all stages of development. Having worked in CROs since 1998, Christine brings extensive experience spanning both operations and commercial leadership. Her background includes Clinical Operations, Clinical Pharmacology, Bioanalytical/Biomarker services, and Central Lab/Kitting, enabling a well-rounded, solutions-focused approach to client engagement. Christine joined KCAS Bio in 2009 following the divestiture from AAIPharma, and has played a key role in the organization’s growth and evolution. Prior to KCAS, she held roles at AAIPharma, Quintiles, and Hoechst Marion Roussel (now Sanofi). She earned a BS in Microbiology from Kansas State University and is based in the San Francisco Bay Area.
Blogs
The benevolent COVID virus has brought our industry many “gifts.” One birthday present is like a jelly of the month club subscription, and it’s impacted all Central Labs and providers of Clinical Sample Collection Kits, without discretion: the shifting un-availability of important kit contents, like vacutainers and polypropylene tubes. While…
Blogs
Biomarkers can be defined and utilized for many purposes. There are disease biomarkers as well as mechanistic or pharmacological biomarkers. To reduce attrition and better understand a therapeutic, it is essential to be able to monitor the effectiveness of the therapeutic during drug development. Measurement of biomarker levels related to…
Blogs
At KCAS, we work with Director, VP, and C-level pharmaceutical and biotech executives that need to measure their drug or the effect of their drug in biological matrix. Many of our customers rely on…
Blogs
If you’re running a clinical or preclinical study, there are many components that you need to think about, plan, and execute. One is “what the heck do I do with these samples we’re collecting”…
Blogs
The 505(b)(2) drug development path, in contrast to traditional development of a new, never been approved drug (described under 505(b)(1) of the Federal Food, Drug, and Cosmetic Act) or ANDA (described under Section 505(j) of the Act) for a generic drug that is no longer under patent…